Short answer
CG Oncology, Inc. (CGON) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $1M (up 1982.7% year over year) with net income of −$60M.
Q1 2026 key financials · XBRL
- Revenue
- $1M
- +1982.7% YoY
- Net income
- −$60M
- −74.7% YoY
- Operating margin
- -6130.1%
- EPS (diluted)
- −$0.71
- −57.8% YoY
Source: XBRL data from the CG Oncology, Inc. (CGON) Q1 2026 10-Q on SEC EDGAR. USD.
CG Oncology, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes to risk factors disclosed in the 2025 Annual Report filed February 27, 2026
- IPO proceeds $399.6 million net, with $340.2 million used by March 31, 2026
- Research and development, manufacturing, and pre-commercial activities funded by remaining IPO proceeds
- Clinical supply dependence on a contract manufacturing organization for cretostimogene
- No newly added regulatory, legal, operational, competitive, or financial risk identified this quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CG Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.